tiprankstipranks
Trending News
More News >
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (HK:1858)
:1858
Hong Kong Market
Advertisement

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis

Compare
0 Followers

Top Page

HK:1858

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H

(1858)

Rating:67Neutral
Price Target:
HK$18.00
▲(8.56%Upside)
The stock exhibits strong technical momentum, supporting a higher score, but this is countered by financial performance concerns due to revenue and cash flow challenges. The high P/E ratio raises valuation concerns, though a strong dividend yield offers some offset. The absence of earnings call data prevents further analysis.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) vs. iShares MSCI Hong Kong ETF (EWH)

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company DescriptionBeijing Chunlizhengda Medical Instruments Co., Ltd., an orthopedic medical device company, engages in the research and development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China. It offers implantable orthopedic medical devices, which consist of joint prosthesis products and spinal products. The company primarily sells its products through distributors, or on ODM and OEM bases under the Chunli brand, as well as to hospitals directly. It also exports its products to various countries. The company was incorporated in 1998 and is headquartered in Beijing, China.
How the Company Makes MoneyBeijing Chunlizhengda Medical Instruments Co., Ltd. generates revenue through the sale of its orthopedic implants and surgical instruments. The company's primary revenue streams include the direct sale of joint prostheses and spinal implants to hospitals, clinics, and healthcare providers. Chunlizhengda also engages in partnerships and collaborations with medical institutions and distributors to expand its market reach. Additionally, the company invests in research and development to continuously improve its product offerings, which helps maintain its competitive edge and drive sales growth. Key factors contributing to its earnings include its robust distribution network, commitment to product quality, and ability to meet the evolving demands of the healthcare sector.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary
The company shows strong balance sheet stability with minimal debt, but faces financial stress due to declining revenue and profitability margins, coupled with negative cash flow from operations. Improving cash generation and revenue is critical for long-term growth.
Income Statement
65
Positive
The gross profit margin remains strong at 64.08% in 2024, indicating efficient cost management in production. However, revenue showed a significant decline of 33.33% from 2023 to 2024, indicating challenges in maintaining sales volumes. The net profit margin also decreased, reflecting reduced profitability. EBIT and EBITDA margins have also decreased, suggesting pressures on operational efficiency.
Balance Sheet
75
Positive
The company maintains a solid equity position with a debt-to-equity ratio of 0.0003, indicating minimal leverage and financial risk. The equity ratio is robust at 81.38%, showcasing strong financial stability. Despite a slight drop in stockholders' equity, the company's balance sheet remains strong.
Cash Flow
40
Negative
The operating cash flow turned negative in 2024, indicating issues in cash generation from core operations. Free cash flow has also declined, pointing to challenges in maintaining liquidity. The free cash flow to net income ratio is negative, highlighting the need for cash management improvements.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue805.86M1.21B1.20B1.11B937.69M
Gross Profit516.49M875.89M913.53M854.54M680.76M
EBITDA169.32M340.65M366.96M360.99M349.78M
Net Income124.99M277.82M307.72M322.36M283.37M
Balance Sheet
Total Assets3.47B3.65B3.41B3.00B1.54B
Cash, Cash Equivalents and Short-Term Investments1.89B2.10B1.72B1.74B690.12M
Total Debt866.44K1.75M1.31M1.23M1.85M
Total Liabilities644.39M770.33M690.07M530.58M460.41M
Stockholders Equity2.82B2.88B2.72B2.47B1.08B
Cash Flow
Free Cash Flow-51.07M478.47M16.10M-34.62M236.68M
Operating Cash Flow-1.90M511.71M41.01M164.79M260.68M
Investing Cash Flow55.84M-81.56M
Financing Cash Flow-183.14M-121.33M1.07B-11.88M

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price16.58
Price Trends
50DMA
12.14
Positive
100DMA
10.64
Positive
200DMA
9.50
Positive
Market Momentum
MACD
1.18
Negative
RSI
73.59
Negative
STOCH
68.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Positive. The current price of 16.58 is above the 20-day moving average (MA) of 13.88, above the 50-day MA of 12.14, and above the 200-day MA of 9.50, indicating a bullish trend. The MACD of 1.18 indicates Negative momentum. The RSI at 73.59 is Negative, neither overbought nor oversold. The STOCH value of 68.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1858.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
HK$8.18B41.004.39%0.07%-32.05%-54.47%
52
Neutral
$7.61B0.11-63.03%2.07%16.35%0.29%
€592.80M-10.43%
€800.37M59.803.22%0.54%
75
Outperform
HK$6.93B22.0510.92%0.18%20.19%45.54%
73
Outperform
HK$5.12B11.618.40%0.17%12.41%
69
Neutral
HK$8.42B36.516.49%0.87%-18.05%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
16.58
8.85
114.49%
DE:4WO
Peijia Medical Ltd.
0.88
0.42
91.30%
DE:818
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
2.44
1.25
105.04%
HK:1302
LifeTech Scientific Corporation
1.99
0.60
43.17%
HK:1763
China Isotope & Radiation Corp.
16.46
6.22
60.74%
HK:1789
AK Medical Holdings Ltd.
6.72
2.39
55.20%

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events

Beijing Chunlizhengda Medical Instruments Discloses Executive Remuneration Details
Jul 23, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. has released supplemental information regarding the remuneration of its chief executive, who is not a director, for the years 2022, 2023, and 2024. The announcement clarifies the emoluments paid, highlighting that no inducement or compensation for loss of office was provided, nor were any emoluments waived by the chief executive in these years. This disclosure provides transparency in the company’s financial reporting and may impact stakeholder perceptions regarding executive compensation practices.

Beijing Chunlizhengda Medical Instruments Holds Successful Adjourned H Shareholders’ Meeting
Jul 7, 2025

The company recently held an Adjourned H Shareholders’ Class Meeting on July 7, 2025, in Beijing, which was convened by the board of directors and chaired by Ms. Shi Wenling. The meeting adhered to the legal and regulatory requirements of the PRC and the Hong Kong Stock Exchange, with voting conducted by a registered poll. All directors attended, either in person or by phone, and there were no restrictions on shareholder voting. The meeting saw attendance from shareholders holding 11.6541% of the total H Shares.

Beijing Chunlizhengda Declares Final Dividend for 2024
Jun 27, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the results of resolutions passed at their 2024 annual general meeting, including the declaration of a final ordinary cash dividend of RMB 0.49 per 10 shares for the financial year ending December 31, 2024. The dividend, approved on June 26, 2025, will be paid in Hong Kong dollars at a rate of HKD 0.5364 per 10 shares, with specific withholding tax rates applied based on shareholder residency. This announcement reflects the company’s commitment to returning value to its shareholders and may impact its financial performance and investor relations positively.

Beijing Chunlizhengda Medical Instruments Passes All Resolutions at 2024 AGM
Jun 26, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. held its 2024 Annual General Meeting and A Shareholders’ Class Meeting on June 26, 2025, where all proposed resolutions were passed. The meeting was conducted in compliance with relevant regulations, and voting was overseen by WUYIGE Certified Public Accountants LLP. Key shareholders abstained from voting on certain resolutions, and there were no stated intentions to oppose any resolutions.

Beijing Chunlizhengda Medical Instruments Adjourns H Shareholders’ Meeting
Jun 25, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the adjournment of its H Shareholders’ Class Meeting due to insufficient voting rights participation. The meeting, initially scheduled for June 26, 2025, will now be held on July 7, 2025. This rescheduling ensures compliance with the company’s articles of association, allowing for adequate shareholder representation and decision-making.

Beijing Chunlizhengda Announces H Shareholders’ Class Meeting for Share Repurchase Mandate
May 27, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for H shareholders to discuss a special resolution regarding the repurchase of H Shares. The proposed mandate would allow the board to repurchase up to 10% of the total H Shares, excluding treasury shares, based on market conditions and company needs. This move could potentially impact the company’s share capital structure and market positioning, reflecting strategic financial management to enhance shareholder value.

Beijing Chunlizhengda Schedules 2024 AGM with Key Resolutions on Agenda
May 27, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for June 26, 2025. Key resolutions to be discussed include the approval of the 2024 profit distribution plan, remuneration for directors and supervisors for 2025, and the re-appointment of auditors. Additionally, a special resolution will consider granting the board a mandate to repurchase up to 10% of its H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.

Beijing Chunlizhengda Announces Leadership Changes in Financial Management
May 27, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the resignation of two senior management members, Mr. Zhai Zhiyong and Ms. Li Yumei, due to personal reasons. Both will continue to serve the company in other capacities. The company appointed Ms. Lu Hongyue as the new Chief Financial Officer, effective immediately, to ensure continuity in financial management. This leadership change is expected to support the company’s ongoing financial strategies and operations.

Beijing Chunlizhengda Medical Instruments Reports Q1 2025 Financial Results
Apr 29, 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. has released its unaudited financial results for the first quarter of 2025, in compliance with the Chinese Accounting Standards for Business Enterprises. The report, available in both Chinese and English, highlights the company’s financial performance for the three months ending March 31, 2025. Stakeholders are advised to consider potential investment risks as the data has not been audited.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025